Unicycive TherapeuticsUNCY
About: Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Employees: 22
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
1.71% less ownership
Funds ownership: 59.44% [Q4 2024] → 57.73% (-1.71%) [Q1 2025]
6% less funds holding
Funds holding: 31 [Q4 2024] → 29 (-2) [Q1 2025]
30% less capital invested
Capital invested by funds: $49M [Q4 2024] → $34.5M (-$14.6M) [Q1 2025]
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Swayampakula Ramakanth | 1,221%upside $9 | Buy Assumed | 27 May 2025 |
Guggenheim Vamil Divan | 781%upside $6 | Buy Initiated | 21 Apr 2025 |
HC Wainwright & Co. Ed Arce | 1,001%upside $7.50 | Buy Reiterated | 11 Apr 2025 |
Financial journalist opinion
Based on 3 articles about UNCY published over the past 30 days









